Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
6.14% $2.94
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 367.79 mill |
EPS: | -0.510 |
P/E: | -5.76 |
Earnings Date: | Apr 30, 2024 |
SharesOutstanding: | 125.10 mill |
Avg Daily Volume: | 0.0844 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -5.76 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.98x |
Company: PE -5.76 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.122 (-104.15%) $-3.06 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 2.74 - 3.14 ( +/- 6.84%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-11 | Patel Sujal M | Buy | 12 044 | Common Stock |
2024-03-08 | Patel Sujal M | Buy | 2 430 | Common Stock |
2024-03-07 | Patel Sujal M | Buy | 18 854 | Common Stock |
2024-03-06 | Patel Sujal M | Buy | 9 267 | Common Stock |
2024-03-05 | Patel Sujal M | Buy | 7 405 | Common Stock |
INSIDER POWER |
---|
94.55 |
Last 97 transactions |
Buy: 21 218 105 | Sell: 5 493 083 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.94 (6.14% ) |
Volume | 0.131 mill |
Avg. Vol. | 0.0844 mill |
% of Avg. Vol | 155.58 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.